MedLab 2018/19 Cohort

At Beyond 700, we are a passionate about changing eye health management. Our team has combined strong technical and commercial expertise to develop a novel device, TearView. This device will enable eye care specialists to visualize diseases of the surface of the eye that are invisible to current technology. In particular, it allows the moist film that covers and nourishes the surface of the eye to be examined and problems diagnosed. When this moist film is faulty or damaged, the use of TearView will let clinicians choose treatment and then monitor the efficacy of the treatment. Often the moist film covering the surface of the eye is damaged by contact lens wear and this can be avoided by using TearView to select contact lenses for an individual that do not interfere with the protective film. Taken together, this will transform clinical eye care and we are excited to be able to manufacture TearView ourselves in Sydney and to sell to a global market.

At Beyond 700, we are a passionate about changing eye health management. Our team has combined strong technical and commercial expertise to develop a novel device, TearView. This device will enable eye care specialists to visualize diseases of the surface of the eye that are invisible to current technology. In particular, it allows the moist film that covers and nourishes the surface of the eye to be examined and problems diagnosed. When this moist film is faulty or damaged, the use of TearView will let clinicians choose treatment and then monitor the efficacy of the treatment. Often the moist film covering the surface of the eye is damaged by contact lens wear and this can be avoided by using TearView to select contact lenses for an individual that do not interfere with the protective film. Taken together, this will transform clinical eye care and we are excited to be able to manufacture TearView ourselves in Sydney and to sell to a global market.

Doclink is a medical intelligence platform extending doctors’ capabilities by connecting them to the cloud’s computing power, deep learning and big data. Doclink enables improvement across the medical spectrum from diagnostic, treatment, monitoring through to the discovery of novel therapeutic targets. Our solutions currently provide clinical decision support to doctors for the screening, early-diagnosis and treatment monitoring of cancer.

Doclink is a medical intelligence platform extending doctors’ capabilities by connecting them to the cloud’s computing power, deep learning and big data. Doclink enables improvement across the medical spectrum from diagnostic, treatment, monitoring through to the discovery of novel therapeutic targets. Our solutions currently provide clinical decision support to doctors for the screening, early-diagnosis and treatment monitoring of cancer.

loop+ is a remote care management platform that supports clinician prescribed care plans and everyday risk management for people with limited mobility.  Sensors are integrated into assistive devices and the home to provide continuous monitoring in everyday life. The feedback loop through the mobile app increases motivation and adherence to care plans, using techniques similar to a fitness tracker.

loop+ is a remote care management platform that supports clinician prescribed care plans and everyday risk management for people with limited mobility.  Sensors are integrated into assistive devices and the home to provide continuous monitoring in everyday life. The feedback loop through the mobile app increases motivation and adherence to care plans, using techniques similar to a fitness tracker.

Neuromersiv is a virtual reality startup enabling therapists and medical professionals to make brain rehabilitation therapy more fun and emotionally engaging. Neuromersiv offers a dedicated, modular and measurable VR patient therapy solution that involves performing simple, gamified self-care tasks using a consumer VR headset and a proprietary wearable to significantly improve compliance and outcomes.

Neuromersiv is a virtual reality startup enabling therapists and medical professionals to make brain rehabilitation therapy more fun and emotionally engaging. Neuromersiv offers a dedicated, modular and measurable VR patient therapy solution that involves performing simple, gamified self-care tasks using a consumer VR headset and a proprietary wearable to significantly improve compliance and outcomes.

ReNATURE Labs is an Australian based biotechnology company: we want to reshape and disrupt world health by transforming injectable only peptides into affordable, and widely available ingestible tablets. Our vision is to increase the longevity of the human race and lifespan – focusing on reducing the rapid increase of autoimmune diseases.  The future focus of ReNATURE Labs is to extend the current oral delivery platform technologies onto more complex, and higher value markets such as oral insulin and oral vaccines.

ReNATURE Labs is an Australian based biotechnology company: we want to reshape and disrupt world health by transforming injectable only peptides into affordable, and widely available ingestible tablets.
Our vision is to increase the longevity of the human race and lifespan – focusing on reducing the rapid increase of autoimmune diseases.

The future focus of ReNATURE Labs is to extend the current oral delivery platform technologies onto more complex, and higher value markets such as oral insulin and oral vaccines.

SDIP is working on next generation of bioresorbable implants. SDIP`s compounds adsorb to the body when the host cells repair the damaged tissue avoiding unnecessary removal surgical interventions. SDIP leaves no acidic by-products behind. The properties of SDIP can be tuned to address different clinical needs in fixing a range of damaged soft and interface tissues. Founders have been funded $940K by NSW government to further support the commercialization of SDIP.

SDIP is working on next generation of bioresorbable implants. SDIP`s compounds adsorb to the body when the host cells repair the damaged tissue avoiding unnecessary removal surgical interventions. SDIP leaves no acidic by-products behind. The properties of SDIP can be tuned to address different clinical needs in fixing a range of damaged soft and interface tissues. Founders have been funded $940K by NSW government to further support the commercialization of SDIP.